Effects of two doses of tibolone on trabecular and cortical bone loss in early postmenopausal women: A two-year randomized, placebo-controlled study

Bone

Volumn 19, Issue 4, 1996, Pages 395-399

  Berning, B ^a   Kuijk, C V ^b   Kuiper, J W ^b   Coelingh Bennink, H J T ^c   Kicovic, P M ^c   Fauser, B C J M ^a,b  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c Research and Development   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; CALCIUM; CREATININE; HYDROXYPROLINE; PHOSPHORUS; TIBOLONE;

ABSORPTIOMETRY; ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE ATROPHY; BONE DENSITY; CALCIUM BLOOD LEVEL; CALCIUM URINE LEVEL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICAL BONE; CREATININE URINE LEVEL; DRUG EFFICACY; FEMALE; HUMAN; HYDROXYPROLINE URINE LEVEL; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHALANX; PHOSPHATE BLOOD LEVEL; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL; TRABECULAR BONE; VERTEBRA;

ANABOLIC AGENTS; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; BONE DENSITY; DENSITOMETRY, X-RAY; FEMALE; HUMANS; LONGITUDINAL STUDIES; MIDDLE AGED; NORPREGNENES; OSTEOPOROSIS, POSTMENOPAUSAL;

EID: 0012953649     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S8756-3282(96)00219-0     Document Type: Article

References (30)

1. 1. Abadalla, H. I., Hart, D. M., Lindsay, R., and Hooke, A. Prevention of bone mineral loss in postmenopausal women by norethisteron. Obstet Gynecol 66:789-792; 1985.
2. 2. Berning, B., van Kuijk, C., Schütte, H. E., Kuiper, J. W., Drogendijk, A.C., and Fauser, B. C. J. M. Determinants of lumbar bone mineral density in normal weight, non-smoking women soon after menopause. A study using clinical data and quantitative computed tomography. Bone Miner 21:129-139; 1993.
3. 3. DeCherney, A. Physiologic and pharmacologic effects of estrogen and progestins on bone. J Reprod Med 38:1007-1014; 1993.
4. 4. Ettinger, B., Genant, H. K., and Cann, C. E. Postmenopausal bone loss is prevented with low-dosage estrogen with calcium. Ann Intern Med 106:40-45; 1987.
5. 5. Fogelman, I., Bessant, G., Smith, M. L., Hart, D. M., and Lindsay, R. Assessment of synthetic steroid (Org OD 14): Effect on skeletal metabolism by 24-H whole retention of diphosphonate. Maturitas 3:265-269; 1981.
6. 6. Gardsel, P., Johnell, O., and Nilsson, B. E. The predictive value of bone loss for fragility fractures in women: A longitudinal study over 15 years. Calcif Tissue Int 49:90-94; 1991.
7. 7. Genant, H. K., Cann, C. E., Ettinger, B., and Gordon, G. S. Quantitative computed tomography of vertebral spongiosa: A sensitive method for detecting early postmenopausal after oophorectomy. Ann Intern Med 97:699-705; 1982.
8. 8. Geusens, P., Dequeker, J., Gielen, J., and Schot, L. P. C. Non-linear increase in vertebral density induced by a synthetic steroid (Org OD 14) in women with established osteoporosis. Maturitas 13:155-162; 1991.
9. 9. Hansson, T. and Roos, H. T. The effect of fluoride and calcium on spinal osteoporosis: A controlled prospective (three years) study. Calcif Tissue Int 40:315; 1987.
10. 10. Kalender, W. A., Felsenberg, D., Genant, H. K., Fisher, M., Dequecker, J., and Reeve, J. The European Spine Phantom - a tool for standardization and quality control in spinal bone mineral measurement by DXA and QCT. Eur J Radiol 20:83-92; 1995.
11. 11. Lindsay, P. C., Shaw, R. C., Coelingh Bennink, H. J., and Kicovic, P. M. The effect of add-back treatment with tibolone (Livial) on patients treated with the gonadotropin-releasing hormone agonist triptorelin (Decapeptyl). Fertil Steril 65:342-348; 1996.
12. 12. Lindsay, R., Hart, D. M., and Kraszewski, A. Prospective double blind trial of synthetic steroid (Org OD 14) for preventing postmenopausal osteoporosis. BMJ 280:1207-1209; 1980.
13. 13. Lyritis, G. P., Karphatios, S., Basdekis, K., Grigoriou, O., Katostaras, T., and Paspati, I., et al. Prevention of post-oophorectomy bone loss with tibolone. Maturitas 22:247-253; 1995.
14. 14. Marslew, U., Overgaard, K., Riis, B. J., and Christiansen, C. Two new combinations of estrogen and progestagen for prevention of postmenopausal bone loss: Long-term effects on bone, climacteric symptoms, and bleeding. Obstet Gynecol 79:202-210; 1992.
15. 15. Munk-Jensen, N., Pors Nielsen, S., Obel, E. B., and Bonne Eriksen, P. Reversal of postmenopausal vertebral bone loss by oestrogen and progestagen: A double blind placebo controlled study. Br Med J 296:1150-1152; 1988.
16. 16. Nilas, L., Borg, J., Gotfredsen, A., and Christiansen, C. Comparison of single-and dual photon absorptiometry in postmenopausal bone mineral loss. J Nucl Med 26:1257-1262; 1985.
17. 17. Nordin, B. E. C., Need, A. G., Morris, H. A., and Horowitz, H. Approaches to the problem of osteoporosis. Clin Orthop Relat Res 200:181-197; 1985.
18. 18. Pacifici, R., McMurtry, C., Vred, I., Rupich, R., and Avioli, L. Coherence therapy does not prevent axial bone loss in osteoporotic women: A preliminary comparative study. J Clin Endocrinol Metab 66:747-753; 1988.
19. 19. Recker, R. R., Kimmel, D. B, and Parfitt, A. M Static and tetracycline based bone histomorphometric data from 34 normal postmenopausal females. J Bone Miner Res 3:133-144; 1988.
20. 20. Reinbold, W. D., Genant, H. K., Reiser, U. J., Harris, S. T., and Ettinger, B. Bone mineral content in early postmenopausal and postmenopausal women: Comparison of measurement methods. Radiology 160:469-478; 1986.
21. 21. Ribot, C., Tremollieres, F., Pouilles, J. M., Louvet, J. P., and Peyron, R. Preventive effects of transdermal administration of 17 B estriadiol on postmenopausal bone loss: A 2-year prospective study. Obstet Gynecol 75(suppl.):42-46; 1990.
22. 22. Riggs, B. L. and Melton, L. J. Involutional osteoporosis. N Engl J Med 314:1676-1686; 1986.
23. 23. Riis, B. J., Thomsen, K., Strom, V., and Christiansen, C. The effect of percutaneous estradiol and natural progesterone on postmenopausal bone loss. Am J Obstet Gynecol 156:61-65; 1987.
24. 24. Rymer, J., Chapman, M. G., and Fogelman, I. Effect of tibolone on postmenopausal bone mass. Osteoporos Int 4:314-319; 1994.
25. 25. Sandor, T., Kalender, W. A., Hanlon, W. B., Weissman, B. N., and Rumbaugh, C. Spinal bone determination using automated contour detection: Application for single and dual energy. CT. SPIE 555:188-194; 1985.
26. 26. Stevenson, J. C., Cust, M. P., Gangar, K. F., Hillard, T. C., Lees, B., and Whitehead, M. I. Effects of transdermal versus oral hormone replacement therapy on bone density in spine and proximal femur in postmenopausal women. Lancet 335:265-269; 1990.
27. 27. Storm, T., Thamsborg, G., Steiniche, T., Genant, H. K., and Sörensen, O. M. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 322:1265-1271; 1990.
28. 28. Tax, L., Goorissen, E. M., and Kicovic, P. M. Clinical profile of Org OD 14. Maturitas (suppl. 1):3-13; 1987.
29. 29. Trouerbach, W. T., Birkenhäger, J. C., Schmitz, P. I. M., van Hemert, A.M., van Saase, J. L. C. M., and Collette, H. J. A., et al. A cross-sectional study of age related loss of mineral content of phalangeal bone in men and women. Skeletal Radiol 17:338-343; 1988.
30. 30. de Visser, J., Coert, A., Feenstra, H., and van der Vies, J. Endocrinology studies with Org OD 14. Arzeneimittelforsch Drug Res 34:1010-1017; 1984.